Sirico, MariannaVirga, AlessandraConte, BenedettaUrbini, MilenaUlivi, PaolaGianni, CaterinaMerloni, FilippoPalleschi, MichelaGasperoni, MarcoCurcio, AnnalisaSaha, DebjaniBuono, GiuseppeMuñoz, MontserratDe Giorgi, UgoSchettini, Francesco2024-07-022024-07-022023-01-011040-8428https://hdl.handle.net/2445/214184Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast conservative surgery and conversions from inoperable to operable hormone receptor-positive (HR+)/HER2-negative breast cancer (BC), with less toxicities than neoadjuvant chemotherapy (NACT) and similar outcomes. Hence, it has been proposed as a logical alternative to NACT in patients with HR+/HER2- BC candidate to a neoadjuvant approach. Nevertheless, potential barriers to the widespread use of NET include the heterogeneous nature of patient response coupled with the long duration needed to achieve a clinical response. However, interest in NET has significantly increased in the last decade, owing to more in-depth investigation of several biomarkers for a more adequate patient selection and on-treatment benefit monitoring, such as PEPI score, Ki67 and genomic assays. This review is intended to describe the state-of-the-art regarding NET, its future perspectives and potential integration with molecular biomarkers for the optimal selection of patients, regimen and duration of (neo)adjuvant treatments.13 p.application/pdfengcc-by (c) Sirico, Marianna et al., 2023http://creativecommons.org/licenses/by/4.0Càncer de mamaMarcadors bioquímicsEndocrinologiaTractament adjuvant del càncerBreast cancerBiochemical markersEndocrinologyAdjuvant treatment of cancerinfo:eu-repo/semantics/article7295972024-07-02info:eu-repo/semantics/openAccess36565894